Please share your phone number so we can contact you to learn about your health complaint.
Opdivo works by boosting the immune system to recognize and attack cancer cells. It blocks the PD-1 protein that cancer cells use to escape immune detection.
It is prescribed for various cancers, including:
Non-small cell lung cancer (NSCLC).
Advanced melanoma.
Head and neck cancers.
Liver cancer.
Kidney and bladder cancers.
Administered via intravenous infusion in a hospital or oncology center.
Usually every 2 or 4 weeks.
Infusion takes about 30 minutes.
Fatigue.
Loss of appetite and weight loss.
Cough or shortness of breath.
Skin rash and itching.
Liver or lung inflammation.
Endocrine gland disorders.
Severe allergy to drug components.
Patients with organ transplants.
Those on strong immunosuppressants.
Opdivo is produced by Bristol-Myers Squibb (BMS), a leading global pharmaceutical company.
In Egypt, Opdivo is available in selected oncology centers, but due to its high cost, careful coordination is required. Macrocare helps by:
Coordinating treatment plans with Opdivo.
Providing treatment options in Egypt and abroad.
Offering step-by-step patient support.
Opdivo (Nivolumab) is a groundbreaking immunotherapy drug that offers real hope for cancer patients. Despite its high cost, its effectiveness makes it one of the most sought-after treatments. With Macrocare, you gain access to world-class treatment protocols and comprehensive care.